Genentech, Amgen settle Neupogen dispute
Executive Summary
Amgen will make a one-time payment to Genentech as part of a Neupogen and Neulasta patent dispute settlement reached Aug. 26. The terms of the settlement were not disclosed, but Genentech's expectation of a $0.20 per-share impact during the third quarter suggests a payment of approximately $105 mil. after taxes. Both sides have agreed to drop all claims and counterclaims. Amgen said it is not taking a license to any of the three disputed Genentech patents (1"The Pink Sheet" Nov. 11, 1996, T&G-3)...